Investor Presentation Q1 2023

19 Investor presentation First three months of 2023 Novo NordiskⓇ Novo Nordisk's opportunity is in the large unmet needs across all therapy areas in scope. Diabetes care 537m people with diabetes¹ ~15% of people in good control² Rare disease Haemophilia 0.6m people with haemophilia4 -35% of people being treated Novo Nordisk Way Driving change to >764m people with obesity³ Obesity care ~2% of people in medically treated defeat diabetes and other serious chronic diseases ustainable business 16% of global deaths caused by ASCVD5 >25m people affected by heart failure6 Other serious chronic diseases >25m people affected by NASH7 >70m people affected by AD³ 1 International Diabetes Federation: Diabetes Atlas 10th edition, 2021; 2Real-world studies indicate between 30-55% of patients reach HbA1c target <7% .e.g. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4388968/, taking 42.5% in good control of treated people; 3 World Diabetes Atlas 2022; 4 WFH annual survey 2020 (120 of 147 countries responded): Prevalence by calculating expected number of patients using 20.9 per 100.000 in haemophilia Identified patients as proxy for receiving some sort of treatment; 5 "The top 10 causes of death", WHO, 9 December 2020 (ASCVD denoted as ischaemic heart disease); "Global Public Health Burden of Heart Failure, Apr. 2017: https://pubmed.ncbi.nlm.nih.gov/28785469/; Estes C, Modeling the epidemic of non-alcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, 2018; 8The World Alzheimer Report 2015, The Global Impact of Dementia, Alzheimer's Disease International (ADI), London.

View entire presentation